Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

2.

Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.

Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, Jackson HA, Mari Aparici C, Carlson D, Maris J, Hawkins R, Matthay KK.

J Clin Oncol. 2009 Nov 10;27(32):5343-9. doi: 10.1200/JCO.2008.20.5732. Epub 2009 Oct 5.

3.

18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.

Papathanasiou ND, Gaze MN, Sullivan K, Aldridge M, Waddington W, Almuhaideb A, Bomanji JB.

J Nucl Med. 2011 Apr;52(4):519-25. doi: 10.2967/jnumed.110.083303. Epub 2011 Mar 18.

4.

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.

Bleeker G, Tytgat GA, Adam JA, Caron HN, Kremer LC, Hooft L, van Dalen EC.

Cochrane Database Syst Rev. 2015 Sep 29;(9):CD009263. doi: 10.1002/14651858.CD009263.pub2. Review.

5.

Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.

Dhull VS, Sharma P, Patel C, Kundu P, Agarwala S, Bakhshi S, Bhatnagar V, Bal C, Kumar R.

Nucl Med Commun. 2015 Oct;36(10):1007-13. doi: 10.1097/MNM.0000000000000347.

PMID:
26049371
6.

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D.

J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. Review.

7.

Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.

Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK.

J Clin Oncol. 2003 Mar 15;21(6):1082-6.

PMID:
12637474
8.

123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.

Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL.

J Nucl Med. 2009 Aug;50(8):1237-43. doi: 10.2967/jnumed.108.060467. Epub 2009 Jul 17.

9.

Abnormal FDG and MIBG Activity in the Bones in a Patient With Neuroblastoma Without Detectable Primary Tumor.

Zhang W, Zhuang H, Servaes S.

Clin Nucl Med. 2016 Aug;41(8):632-3. doi: 10.1097/RLU.0000000000001134.

PMID:
26825196
10.

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.

Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI.

Urology. 2002 Jun;59(6):913-8.

PMID:
12031380
11.

PET/CT imaging in neuroblastoma.

Piccardo A, Lopci E, Conte M, Foppiani L, Garaventa A, Cabria M, Villavecchia G, Fanti S, Cistaro A.

Q J Nucl Med Mol Imaging. 2013 Mar;57(1):29-39. Review.

PMID:
23474633
12.

¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma.

Melzer HI, Coppenrath E, Schmid I, Albert MH, von Schweinitz D, Tudball C, Bartenstein P, Pfluger T.

Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1648-58. doi: 10.1007/s00259-011-1843-8. Epub 2011 May 27.

PMID:
21617976
13.

Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.

Claudiani F, Stimamiglio P, Bertolazzi L, Cabria M, Conte M, Villavecchia GP, Garaventa A, Lanino E, De Bernardi B, Scopinaro G.

Q J Nucl Med. 1995 Dec;39(4 Suppl 1):21-4.

PMID:
9002744
14.

Evaluation of morphological/immunohistochemical versus nuclear medicine imaging modalities in detecting metastatic bone and/or marrow deposits in neuroblastoma patients.

Zaher Ael-S, Zaher AM, Moneer MM, El Gamal BM.

J Egypt Natl Canc Inst. 2011 Jun;23(2):79-88. doi: 10.1016/j.jnci.2011.09.004. Epub 2011 Oct 10.

15.

The role of 131 iodine-metaiodobenzylguanidine scanning in the correlative imaging of patients with neuroblastoma.

Andrich MP, Shalaby-Rana E, Movassaghi N, Majd M.

Pediatrics. 1996 Feb;97(2):246-50.

PMID:
8584386
16.

Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.

Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC.

Radiology. 1996 Jun;199(3):743-50.

PMID:
8637999
17.

Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma.

Shulkin BL, Shapiro B, Hutchinson RJ.

J Nucl Med. 1992 Oct;33(10):1735-40.

18.

Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.

Nuñez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM.

J Nucl Med. 2002 Jan;43(1):46-55.

19.

Prognostic value of ¹⁸F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma.

Piccardo A, Puntoni M, Lopci E, Conte M, Foppiani L, Sorrentino S, Morana G, Naseri M, Cistaro A, Villavecchia G, Fanti S, Garaventa A.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1046-56. doi: 10.1007/s00259-014-2691-0. Epub 2014 Feb 22.

PMID:
24562643
20.

Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases.

Chang CY, Gill CM, Joseph Simeone F, Taneja AK, Huang AJ, Torriani M, Bredella MA.

Acta Radiol. 2016 Jan;57(1):58-65. doi: 10.1177/0284185114564438. Epub 2014 Dec 22.

PMID:
25533313

Supplemental Content

Support Center